Frontiers in Oncology (Nov 2022)

Development of a novel nomogram for predicting clinically significant prostate cancer with the prostate health index and multiparametric MRI

  • Li-Cai Mo,
  • Xian-Jun Zhang,
  • Hai-Hong Zheng,
  • Xiao-peng Huang,
  • Lin Zheng,
  • Zhi-Rui Zhou,
  • Jia-Jia Wang

DOI
https://doi.org/10.3389/fonc.2022.1068893
Journal volume & issue
Vol. 12

Abstract

Read online

IntroductionOn prostate biopsy, multiparametric magnetic resonance imaging (mpMRI) and the Prostate Health Index (PHI) have allowed prediction of clinically significant prostate cancer (csPCa).MethodsTo predict the likelihood of csPCa, we created a nomogram based on a multivariate model that included PHI and mpMRI. We assessed 315 males who were scheduled for prostate biopsies.ResultsWe used the Prostate Imaging Reporting and Data System version 2 (PI-RADS V2) to assess mpMRI and optimize PHI testing prior to biopsy. Univariate analysis showed that csPCa may be identified by PHI with a cut-off value of 77.77, PHID with 2.36, and PI-RADS with 3 as the best threshold. Multivariable logistic models for predicting csPCa were developed using PI-RADS, free PSA (fPSA), PHI, and prostate volume. A multivariate model that included PI-RADS, fPSA, PHI, and prostate volume had the best accuracy (AUC: 0.882). Decision curve analysis (DCA), which was carried out to verify the nomogram’s clinical applicability, showed an ideal advantage (13.35% higher than the model that include PI-RADS only).DiscussionIn conclusion, the nomogram based on PHI and mpMRI is a valuable tool for predicting csPCa while avoiding unnecessary biopsy as much as possible.

Keywords